Navidea Biopharmaceuticals Inc

Type: Company
Name: Navidea Biopharmaceuticals Inc
First reported 17 hours ago - Updated 13 hours ago - 1 reports

S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)

Document Format FilesSeq Description Document Type Size 1 POST-EFFECTIVE AMENDMENT NO. 1 v389223_s-8pos.htm S-8 POS 26683 Complete submission text file 0001144204-14-056126.txt 278 ... [Published SEC - 17 hours ago]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Monday Moves: September 15

Share this article:MANUFACTURERPurdue Pharma announced that  Susie Robinson , former head of human resources at Lumeris, has joined the company as Vice President of Human Resources. Prior to Lumeris, Robinson was the chief human resources officer at Infogroup, ... [Published Medical Marketing And Media - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Navidea and Hainan sign agreement for development of lymphatic mapping agent

Navidea Biopharmaceuticals, Inc. has entered into an exclusive agreement with a wholly-owned subsidiary of Hainan Sinotau Pharmaceutical Co., Ltd. to develop and commercialize Lymphoseek Injection, a lymphatic mapping agent, in China. In exchange, Navidea ... [Published Individual.com - Sep 12 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

NAVIDEA BIOPHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.On September 4, 2014 , Navidea Biopharmaceuticals, Inc. (the "Company") issued apress release announcing an exclusive agreement with a wholly-owned subsidiaryof Hainan Sinotau Pharmaceutical Co., Ltd. A copy of the Company's September ... [Published 4 Traders - Sep 10 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Agilis Biotherapeutics Names Dr. Mark J. Pykett as President and Chief Executive Officer

Agilis Biotherapeutics, LLC, a synthetic biology-based company focusedon developing DNA-based therapeutics for rare genetic diseases,announced today the appointment of Dr. Mark Pykett as President and CEO.Dr. Pykett, brings more than 20 years of scientific, ... [Published RCL Advisors - Sep 10 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Navidea Enters Agreement with Hainan Sinotau Pharmaceutical Co.

Navidea Biopharmaceuticals has entered an exclusive agreement with a wholly-owned subsidiary of Hainan Sinotau Pharmaceutical Co. who will develop and commercialize Lymphoseek Injection in China. According to a media release, in exchange, Navidea will ... [Published Individual.com - Sep 10 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Navidea inks agreement with Hainan Sinotau Pharma to develop & market Lymphoseek in China

Navidea Biopharmaceuticals has entered an exclusive agreement with a wholly-owned subsidiary of Hainan Sinotau Pharmaceutical Co., Ltd., a pharmaceutical organisation with a broad China focus in oncology and other therapeutic areas, who will develop and ... [Published PharmaBiz - Sep 08 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Week In Review: DXY Receives $70 Million Investment From Tencent

Deals and FinancingsDXY Group, China's largest healthcare portal, received a $70 million investment from Tencent Holdings (HK: 00700, OTCPK:TCEHY ) in return for an unspecified minority stake in DXY. Tencent is a China internet and mobile phone services ... [Published Seeking Alpha - Sep 08 2014]
First reported Sep 05 2014 - Updated Sep 06 2014 - 2 reports

Hainan Sinotau InLicenses Radiopharmaceutical from Navidea of the US

Hainan Sinotau Pharma and Navidea Biopharma of the US struck a deal under which Sinotau will have rights to develop and commercialize Lymphoseek® Injection in China. Lymphoseek is a radiopharmaceutical developed by Navidea to detect lymph nodes i...Related ... [Published BioPortfolio - Sep 06 2014]
First reported Sep 04 2014 - Updated Sep 05 2014 - 8 reports

Navidea inks deal with Hainan to develop, commercialize Lymphoseek in China

Navidea Biopharmaceuticals has entered an exclusive agreement with a subsidiary of Hainan Sinotau Pharmaceutical to develop and commercialize Lymphoseek (technetium Tc 99m tilmanocept) Injection in China. ... [Published PBR - News - Sep 05 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Commit To Purchase Navidea Biopharmaceuticals At $1, Earn 15.7% Annualized Using Options

Investors considering a purchase of Navidea Biopharmaceuticals, Inc. (NAVB) stock, but tentative about paying the going market price of $1.29/share, might benefit from considering selling puts among the alternative strategies at their disposal..Related ... [Published CEOWorld Magazine - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Navidea Biopharmaceuticals Short Interest Up 0.3% in August (NAVB)

Navidea Biopharmaceuticals (NYSE:NAVB) was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 24,198,923 shares, a growth of 0.3% from the July 31st total of 24,116,182 shares, reports. ... [Published American Banking News - Aug 27 2014]

Quotes

...proprietary Medicinal Nanoengineering platform to develop targeted therapeutics across a range of therapeutic indications," said Amy Schulman. "I'm pleased to play a role in further establishing BIND as a leader in nanomedicine by developing important therapeutics designed to maximize patient benefit."
"Dr. Pykett is highly accomplished in his field and brings to Agilis extensive management and leadership experience along with a record of strong scientific and business development achievement in public and private healthcare companies. We are excited to work closely with Mark to develop life-changing medicines and drive Agilis toward a global leadership position in rare diseases" said G Houston Hall, Managing Director and Executive Chairman of Agilis Biotherapeutics
...and manufacturing with our extensive development, regulatory, sales, and marketing capabilities," commented Xu Xinsheng, Sinotau President and CEO. "The goal will be to offer a novel radiopharmaceutical to potentially spare patients from unnecessary surgery and which can play a critical role in staging and directing cancer treatment. We look forward to giving physicians this new tool in the fight against the many types of cancers common in China, such as breast, oral, and gastric cancers and contributing to bettering the lives of those afflicted with these conditions."

More Content

All (148) | News (42) | Reports (0) | Blogs (101) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (000... [Published SEC - 17 hours ago]
Monday Moves: September 15 [Published Medical Marketing And Media - Sep 15 2014]
BIND Therapeutics Appoints Two New Board Members [Published Pharmacy Choice - Sep 15 2014]
Agilis Biotherapeutics Appoints Pykett as Presi... [Published Individual.com - Sep 15 2014]
Navidea and Hainan sign agreement for developme... [Published Individual.com - Sep 12 2014]
Agilis Biotherapeutics Names Dr. Mark J. Pykett... [Published RCL Advisors - Sep 10 2014]
NAVIDEA BIOPHARMACEUTICALS : Other Events, Fina... [Published 4 Traders - Sep 10 2014]
Navidea Enters Agreement with Hainan Sinotau Ph... [Published Individual.com - Sep 10 2014]
Navidea inks agreement with Hainan Sinotau Phar... [Published PharmaBiz - Sep 08 2014]
Week In Review: DXY Receives $70 Million Invest... [Published Seeking Alpha - Sep 08 2014]
Hainan Sinotau InLicenses Radiopharmaceutical f... [Published BioPortfolio - Sep 06 2014]
Hainan Sinotau In-Licenses Radiopharmaceutical ... [Published BioSpace - Sep 05 2014]
Navidea inks deal with Hainan to develop, comme... [Published PBR - News - Sep 05 2014]
Steve Brozak: Big-Picture Biotech Stocks Rule t... [Published Stockboard Media Inc. - Sep 05 2014]
Navidea signs China commercialization deal for ... [Published Vision Monday - Sep 04 2014]
Navidea eyes China with partnership for Lymphos... [Published MassDevice - Sep 04 2014]
Navidea signs China commercialization deal for ... [Published Business First of Buffalo - Sep 04 2014]
Navidea Enters Lymphoseek® Development and Comm... [Published Investor's Business Daily - Sep 04 2014]
Navidea Enters Lymphoseek® Development and Comm... [Published Fort Mills Times - Sep 04 2014]
Navidea Enters Lymphoseek® Development and Comm... [Published Industrial Info Financials - Sep 04 2014]
Navidea Enters Lymphoseek® Development and Comm... [Published Business Wire Health News - Sep 04 2014]
Constellation Energy Partners Llc (CEP) is Top ... [Published Equities.com - Aug 29 2014]
Leading Health Care Stock for Small-Cap Stars i... [Published Equities.com - Aug 29 2014]
Commit To Purchase Navidea Biopharmaceuticals A... [Published CEOWorld Magazine - Aug 28 2014]
Navidea Biopharmaceuticals Short Interest Up 0.... [Published American Banking News - Aug 27 2014]
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Leading Small-Cap Stars Health Care Stock for A... [Published 4 Traders - Aug 16 2014]
Leading Small-Cap Stars Health Care Stock for A... [Published Equities.com - Aug 15 2014]
Navidea Announces Second Quarter 2014 Financial... [Published EON Science - Aug 06 2014]
Navidea Announces Second Quarter 2014 Financial... [Published Business Wire Science: Science News - Aug 06 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Navidea inks deal with Hainan to develop, comme... [Published PBR - News - Sep 05 2014]
Navidea Biopharmaceuticals has entered an exclusive agreement with a subsidiary of Hainan Sinotau Pharmaceutical to develop and commercialize Lymphoseek (technetium Tc 99m tilmanocept) Injection in China. ...
Navidea Enters Lymphoseek® Development and Comm... [Published Business Wire Health News - Sep 04 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea signs a development and commercialization agreement for Lymphoseek with Hainan Sinotau Pharmaceutical aimed at gaining regulatory approval with China FDA and sales in China. ...
Navidea Announces Second Quarter 2014 Financial... [Published EON Science - Aug 06 2014]
DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea reported Q2 2014 financial results with revenue to Navidea from sales of Lymphoseek® growing to more than $1 million in Q2/2014 and reiterated revenue expectation of $5-6M for full-year 2014. ...
Navidea Announces Second Quarter 2014 Financial... [Published Business Wire Science: Science News - Aug 06 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea reported Q2 2014 financial results with revenue to Navidea from sales of Lymphoseek® growing to more than $1 million in Q2/2014 and reiterated revenue expectation of $5-6M for full-year 2014. ...
Navidea Announces Second Quarter 2014 Financial... [Published Business Wire Health News - Aug 06 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea reported Q2 2014 financial results with revenue to Navidea from sales of Lymphoseek® growing to more than $1 million in Q2/2014 and reiterated revenue expectation of $5-6M for full-year 2014. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Navidea Announces Restructuring of Pipeline Dev... [Published GlobeNewswire: Advertising News - May 15 2014]
Technical Data on Biotech Equities -- Research ... [Published Financial Services - May 14 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.